SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Peter Silsbee who wrote (2683)11/7/1997 4:59:00 PM
From: JOHN W.  Read Replies (1) of 6136
 
You are right. After thinking about it they do conflict.

My thought was that Viracept is there only product that will facilitate the continued development of the pipeline. If Viracept's continued growth continues, then the intrinsic value of the company (their technology and the pipeline) will appear in the stock price.

I guess in a sense then Viracept could be the same as Agouron's future
since the drug had to be a hit for the survival of the company, and therefore the statements are contradictory. However, it is my opinion that Viracept has surpassed the company's own expectations and protease inhibitor mkt will continue to grow in the next 3-5 yrs. The future of the company is secured and the major risk on the ability of Viracept to be marketed and compete has been overcomed.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News